Literature DB >> 22334016

Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity.

Julia D Suerth1, Tobias Maetzig, Martijn H Brugman, Niels Heinz, Jens-Uwe Appelt, Kerstin B Kaufmann, Manfred Schmidt, Manuel Grez, Ute Modlich, Christopher Baum, Axel Schambach.   

Abstract

Comparative integrome analyses have highlighted alpharetroviral vectors with a relatively neutral, and thus favorable, integration spectrum. However, previous studies used alpharetroviral vectors harboring viral coding sequences and intact long-terminal repeats (LTRs). We recently developed self-inactivating (SIN) alpharetroviral vectors with an advanced split-packaging design. In a murine bone marrow (BM) transplantation model we now compared alpharetroviral, gammaretroviral, and lentiviral SIN vectors and showed that all vectors transduced hematopoietic stem cells (HSCs), leading to comparable, sustained multilineage transgene expression in primary and secondary transplanted mice. Alpharetroviral integrations were decreased near transcription start sites, CpG islands, and potential cancer genes compared with gammaretroviral, and decreased in genes compared with lentiviral integrations. Analyzing the transcriptome and intragenic integrations in engrafting cells, we observed stronger correlations between in-gene integration targeting and transcriptional activity for gammaretroviral and lentiviral vectors than for alpharetroviral vectors. Importantly, the relatively "extragenic" alpharetroviral integration pattern still supported long-term transgene expression upon serial transplantation. Furthermore, sensitive genotoxicity studies revealed a decreased immortalization incidence compared with gammaretroviral and lentiviral SIN vectors. We conclude that alpharetroviral SIN vectors have a favorable integration pattern which lowers the risk of insertional mutagenesis while supporting long-term transgene expression in the progeny of transplanted HSCs.

Entities:  

Mesh:

Year:  2012        PMID: 22334016      PMCID: PMC3345992          DOI: 10.1038/mt.2011.309

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  49 in total

1.  Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors.

Authors:  A Schambach; D Mueller; M Galla; M M A Verstegen; G Wagemaker; R Loew; C Baum; J Bohne
Journal:  Gene Ther       Date:  2006-06-08       Impact factor: 5.250

2.  Physiological promoters reduce the genotoxic risk of integrating gene vectors.

Authors:  Daniela Zychlinski; Axel Schambach; Ute Modlich; Tobias Maetzig; Johann Meyer; Elke Grassman; Anjali Mishra; Christopher Baum
Journal:  Mol Ther       Date:  2008-03-04       Impact factor: 11.454

3.  Integration targeting by avian sarcoma-leukosis virus and human immunodeficiency virus in the chicken genome.

Authors:  Stephen D Barr; Jeremy Leipzig; Paul Shinn; Joe R Ecker; Frederic D Bushman
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.

Authors:  Ute Modlich; Jens Bohne; Manfred Schmidt; Christof von Kalle; Sabine Knöss; Axel Schambach; Christopher Baum
Journal:  Blood       Date:  2006-07-06       Impact factor: 22.113

5.  Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression.

Authors:  A Schambach; J Bohne; C Baum; F G Hermann; L Egerer; D von Laer; T Giroglou
Journal:  Gene Ther       Date:  2006-04       Impact factor: 5.250

6.  Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.

Authors:  Axel Schambach; Jens Bohne; Saurabh Chandra; Elke Will; Geoffrey P Margison; David A Williams; Christopher Baum
Journal:  Mol Ther       Date:  2005-10-12       Impact factor: 11.454

7.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

8.  Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells.

Authors:  Brian C Beard; David Dickerson; Kate Beebe; Christina Gooch; James Fletcher; Tulin Okbinoglu; Daniel G Miller; Michael A Jacobs; Rajinder Kaul; Hans-Peter Kiem; Grant D Trobridge
Journal:  Mol Ther       Date:  2007-04-17       Impact factor: 11.454

9.  Hot spots of retroviral integration in human CD34+ hematopoietic cells.

Authors:  Claudia Cattoglio; Giulia Facchini; Daniela Sartori; Antonella Antonelli; Annarita Miccio; Barbara Cassani; Manfred Schmidt; Christof von Kalle; Steve Howe; Adrian J Thrasher; Alessandro Aiuti; Giuliana Ferrari; Alessandra Recchia; Fulvio Mavilio
Journal:  Blood       Date:  2007-05-16       Impact factor: 22.113

10.  Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells.

Authors:  Fang Zhang; Susannah I Thornhill; Steven J Howe; Meera Ulaganathan; Axel Schambach; Joanna Sinclair; Christine Kinnon; H Bobby Gaspar; Michael Antoniou; Adrian J Thrasher
Journal:  Blood       Date:  2007-04-24       Impact factor: 22.113

View more
  34 in total

Review 1.  Development of gene therapy for blood disorders: an update.

Authors:  Arthur W Nienhuis
Journal:  Blood       Date:  2013-07-10       Impact factor: 22.113

2.  MicroRNA target sites as genetic tools to enhance promoter-reporter specificity for the purification of pancreatic progenitor cells from differentiated embryonic stem cells.

Authors:  Ulf Diekmann; Matthias Elsner; Jan Fiedler; Thomas Thum; Sigurd Lenzen; Ortwin Naujok
Journal:  Stem Cell Rev Rep       Date:  2013-10       Impact factor: 5.739

3.  Evaluating a ligation-mediated PCR and pyrosequencing method for the detection of clonal contribution in polyclonal retrovirally transduced samples.

Authors:  Martijn H Brugman; Julia D Suerth; Michael Rothe; Sebastian Suerbaum; Axel Schambach; Ute Modlich; Olga Kustikova; Christopher Baum
Journal:  Hum Gene Ther Methods       Date:  2013-03-14       Impact factor: 2.396

Review 4.  Biosafety features of lentiviral vectors.

Authors:  Axel Schambach; Daniela Zychlinski; Birgitta Ehrnstroem; Christopher Baum
Journal:  Hum Gene Ther       Date:  2013-02       Impact factor: 5.695

5.  Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia.

Authors:  Dirk Heckl; Adrian Schwarzer; Reinhard Haemmerle; Doris Steinemann; Cornelia Rudolph; Britta Skawran; Sabine Knoess; Johanna Krause; Zhixiong Li; Brigitte Schlegelberger; Christopher Baum; Ute Modlich
Journal:  Mol Ther       Date:  2012-04-03       Impact factor: 11.454

6.  Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells.

Authors:  D Hoffmann; J W Schott; F K Geis; L Lange; F-J Müller; D Lenz; D Zychlinski; D Steinemann; M Morgan; T Moritz; A Schambach
Journal:  Gene Ther       Date:  2017-04-20       Impact factor: 5.250

Review 7.  The retroviral vector family: something for everyone.

Authors:  Carina Elsner; Jens Bohne
Journal:  Virus Genes       Date:  2017-07-31       Impact factor: 2.332

8.  Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration.

Authors:  Saumya Shree Gupta; Tobias Maetzig; Goedele N Maertens; Azar Sharif; Michael Rothe; Magdalena Weidner-Glunde; Melanie Galla; Axel Schambach; Peter Cherepanov; Thomas F Schulz
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

9.  Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform.

Authors:  Juwita Hübner; Shahabuddin S Hoseini; Julia D Suerth; Dirk Hoffmann; Marcel Maluski; Jessica Herbst; Holger Maul; Arnab Ghosh; Britta Eiz-Vesper; Qinggong Yuan; Michael Ott; Michael Heuser; Axel Schambach; Martin G Sauer
Journal:  Mol Ther       Date:  2016-05-03       Impact factor: 11.454

10.  Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing.

Authors:  Kerstin B Kaufmann; Christian Brendel; Julia D Suerth; Uta Mueller-Kuller; Linping Chen-Wichmann; Joachim Schwäble; Shweta Pahujani; Hana Kunkel; Axel Schambach; Christopher Baum; Manuel Grez
Journal:  Mol Ther       Date:  2012-12-04       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.